RELUMINATE Trademark

Trademark Overview

On Tuesday, June 13, 2017, a trademark application was filed for RELUMINATE with the United States Patent and Trademark Office. The USPTO has given the RELUMINATE trademark a serial number of 87486030. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 28, 2021. This trademark is owned by Alkermes Pharma Ireland Limited. The RELUMINATE trademark is filed in the Pharmaceutical Products category with the following description:

Prescription pharmaceutical preparations for the treatment of diseases mediated by an opioid receptor, namely, major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression, premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar I disorder, bipolar II disorder and cyclothymic disorder, anxiety, post-traumatic stress disorder, obsessive compulsive disorder and borderline personality disorder
reluminate

General Information

Serial Number87486030
Word MarkRELUMINATE
Filing DateTuesday, June 13, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 28, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 27, 2018

Trademark Statements

Goods and ServicesPrescription pharmaceutical preparations for the treatment of diseases mediated by an opioid receptor, namely, major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression, premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar I disorder, bipolar II disorder and cyclothymic disorder, anxiety, post-traumatic stress disorder, obsessive compulsive disorder and borderline personality disorder

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 19, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAlkermes Pharma Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDUBLIN
IE
Party NameAlkermes Pharma Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDUBLIN
IE

Trademark Events

Event DateEvent Description
Monday, June 28, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 28, 2021ABANDONMENT - NO USE STATEMENT FILED
Saturday, November 7, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 6, 2020EXTENSION 5 GRANTED
Thursday, October 29, 2020EXTENSION 5 FILED
Friday, November 6, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, October 29, 2020TEAS EXTENSION RECEIVED
Wednesday, April 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 20, 2020EXTENSION 4 GRANTED
Monday, April 20, 2020EXTENSION 4 FILED
Monday, April 20, 2020TEAS EXTENSION RECEIVED
Friday, November 1, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 30, 2019EXTENSION 3 GRANTED
Wednesday, October 30, 2019EXTENSION 3 FILED
Wednesday, October 30, 2019TEAS EXTENSION RECEIVED
Wednesday, May 22, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 20, 2019EXTENSION 2 GRANTED
Monday, May 20, 2019EXTENSION 2 FILED
Monday, May 20, 2019TEAS EXTENSION RECEIVED
Tuesday, September 4, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 31, 2018EXTENSION 1 GRANTED
Friday, August 31, 2018EXTENSION 1 FILED
Friday, August 31, 2018TEAS EXTENSION RECEIVED
Tuesday, May 22, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 27, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 27, 2018PUBLISHED FOR OPPOSITION
Wednesday, March 7, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 20, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, February 3, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 2, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 2, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 4, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, August 4, 2017NON-FINAL ACTION E-MAILED
Friday, August 4, 2017NON-FINAL ACTION WRITTEN
Friday, July 21, 2017ASSIGNED TO EXAMINER
Monday, June 19, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, June 16, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

reluminate disorder depression bipolar depressive premenstrual treatment major disorders dysphoric affective